Medical Laboratory Scientist common mistakes
Medical Laboratory Scientist · Understand the traps and how to avoid them.
Reporting a positive antibody screen as 'anti-D' or 'anti-Kell' based only on the panel reaction pattern, without completing the rule-out (excluding) process or confirming with selected cells and enzyme/chemical-treated cells.
Candidates memorize common alloantibody patterns and stop at the first plausible fit; they skip the systematic exclusion of antigens on each reactive cell, so they miss a second antibody or misidentify the specificity when dosage or a high-frequency antigen is involved.
What to do instead
Work every panel with a written rule-out grid: list each reactive cell's antigens, cross off specificities excluded by nonreactive cells, then confirm the surviving candidate with at least two additional cells (including homozygous/heterozygous dosage cells) and treated cells (DTT, ficin, ZZAP) where indicated. Practice until the grid, not pattern recognition, drives the answer.
Treating a positive direct antiglobulin test as automatically diagnostic of autoimmune hemolysis and answering the case with steroids, rather than first determining IgG vs C3d coating and the eluate reactivity.
The DAT is taught as a yes/no test in review material, so candidates forget that a positive DAT with a negative eluate and no evidence of hemolysis (e.g., drug-induced or post-transfusion) has a completely different interpretation and next step.
What to do instead
For every DAT question, answer in sequence: polyspecific result, monospecific IgG and C3d, eluate reactivity pattern, and correlation with hemoglobin, bilirubin, LDH, and haptoglobin. Match the pattern to the differential (warm AIHA = IgG only; cold agglutinin = C3d; drug = variable) before selecting management.
Correcting sodium or glucose results for hyperproteinemia or hyperlipidemia by applying a formula rather than recognizing the need for direct potentiometry or an alternative method.
Candidates memorize pseudohyponatremia as a fact but cannot connect it to the indirect ion-selective electrode method used on most analyzers, so they pick the calculated correction instead of the method change.
What to do instead
Learn the mechanism: indirect ISE dilutes the sample, so electrolyte concentration per volume of plasma water falls when protein or lipid displaces water. The fix is direct ISE (undiluted) or osmolality measurement, not arithmetic correction. Practice distinguishing this from hyperglycemic dilutional hyponatremia, which is corrected.
Interpreting a prolonged aPTT with a normal PT as a factor deficiency and answering 'factor VIII or IX deficiency' without first running the mixing study and looking at the immediate versus incubated result.
Textbook teaching emphasizes hemophilia, and candidates skip the mixing study logic; they also forget that a time-dependent inhibitor (factor VIII inhibitor) corrects at zero minutes and prolongs after incubation.
What to do instead
Memorize the mixing study decision tree: immediate correction that holds at 37°C = factor deficiency; no correction = immediate-acting inhibitor (heparin, lupus anticoagulant, specific inhibitor); correction at 0 min but prolongation at 1–2 h = time-dependent inhibitor such as factor VIII. Then confirm with specific factor assays and, for lupus anticoagulant, the DRVVT or hexagonal-phase phospholipid test.
Classifying a leukemia from morphology and a single immunophenotype marker instead of integrating the full flow cytometry panel with the blast count and cytogenetics.
Candidates anchor on one striking finding (e.g., Auer rods = AML) and ignore cases where mixed phenotype, ambiguous lineage, or a marker like CD19 in a myeloid leukemia changes the diagnosis and therapy.
What to do instead
Build a panel-based framework: myeloid (MPO, CD13, CD33, CD117), B-lymphoid (CD19, CD22, CD79a, TdT), T-lymphoid (CD3, CD7), and immature markers (CD34, HLA-DR). For each case, state the blast percentage, the lineage-defining markers, and the recurrent cytogenetic lesion before naming the entity, and flag cases needing WHO integrated diagnosis.
Answering an immunoassay interference question by repeating the same assay on the same platform, rather than ordering serial dilution, heterophile blocking, or an alternative method.
Candidates equate 'repeat and confirm' with quality practice, but for suspected heterophile antibody, biotin, or macro-complex interference, repeating on the same platform reproduces the false result.
What to do instead
Learn the interference triage: non-linear result on dilution suggests immunoassay interference; heterophile blocking tubes or mouse immunoglobulin blocking addresses human anti-mouse antibodies; biotin interference is resolved by stopping supplements or using a non-biotin assay; macro-enzyme complexes are detected by PEG precipitation or gel filtration. Select the method change, not the repeat.
Choosing a Westgard rule response without checking whether the violation is random or systematic, or whether the control result crosses more than one rule at once.
Candidates memorize rule names (1-2s, 2-2s, R-4s, 4-1s, 10x) but not their error-type mapping, so they select a rejection rule for a shift that is actually a trend, or accept a 1-3s as warning when it is a rejection.
What to do instead
Map rules to error type: 1-2s is a warning only; 1-3s, R-4s, and 2-2s detect random error; 4-1s, 10x, and 2-2s detect systematic error. On each question, name the violated rule, classify the error, then state the corrective action (recalibrate, new reagent lot, instrument service) that matches that class.
Reporting a sputum or wound culture result based on the predominant organism without applying specimen quality screening (Gram stain, squamous epithelial cells per low-power field) or distinguishing colonization from infection.
Candidates focus on identification and susceptibility and skip the preanalytical quality judgment that determines whether the culture should be worked up at all.
What to do instead
For respiratory specimens, apply the Bartlett or Murray–Washington criteria (e.g., >10 squamous epithelial cells/LPF indicates oral contamination; <10 with >25 PMNs is acceptable). For wounds, correlate with collection method (aspirate vs swab) and note that mixed flora often reflects colonization. Answer with the quality assessment alongside the organism.
Interpreting a molecular result (e.g., a quantitative viral load or a resistance mutation) without checking the assay's limit of detection, linear range, and whether the result is log-transformed or IU/mL versus copies/mL.
Candidates treat all molecular results as directly comparable, so they misread a 1-log change as clinically significant when it is within assay variability, or compare results across platforms with different units.
What to do instead
Before interpreting, identify the assay's limit of detection and linear range, the unit (IU/mL standardized to WHO vs copies/mL), and the assay's stated variability. Apply the accepted threshold for clinical significance (e.g., a confirmed ≥0.5 or 1 log10 change for viral load monitoring) and note when a change requires repeat testing on the same platform.
Selecting the order of draw or the correct tube/additive from memory of a single mnemonic, and applying the same sequence to capillary and venous collections or to coagulation and blood bank specimens.
Mnemonics compress the CLSI order of draw into a phrase that candidates apply rigidly, missing exceptions such as blood culture before other tubes, coagulation tubes requiring full draw and specific fill volume, and the discard tube for butterfly collections.
What to do instead
Reconstruct the order from additive logic: blood cultures first, then sodium citrate (coagulation), serum tubes with or without clot activator, heparin, EDTA, and glycolytic inhibitor tubes last. For each question, state the additive, the required fill volume (citrate 9:1 ratio), and the special handling (discard tube, mixing, timing) before choosing the tube.